Organovo Presents Data Supporting 3D Bioprinted Liver Tissues for Drug Toxicity Testing and Liver Fibrosis Modeling

Emerging Technology

Organovo Holdings, Inc. (NYSEMKT:ONVO) announced five presentations at the Society of Toxicology’s to demonstrate the broad applicability of Organovo’s exVive3DTM Human Liver Model for the assessment of drug safety and the detection of multiple clinically-relevant modes of liver injury, including steatosis and fibrosis.

Organovo Holdings, Inc. (NYSEMKT:ONVO) announced five presentations at the Society of Toxicology’s to demonstrate the broad applicability of Organovo’s exVive3DTM Human Liver Model for the assessment of drug safety and the detection of multiple clinically-relevant modes of liver injury, including steatosis and fibrosis.
According to Dr. Sharon Presnell, chief technology officer and executive vice president of research & development, Organovo:

Drug-induced liver injury remains a major cause of late-stage clinical failures and market withdrawal, often due to poor translation from preclinical animal studies to clinical outcomes. Organovo’s exVive3D human liver model replicates complex cell-cell interactions and key elements of native tissue architecture to enable the detection of multiple clinically-relevant modes of tissue injury, including necrosis, immune-mediated tissue damage, steatosis, and fibrosis.  When a preclinical or clinical-stage asset presents a challenging safety or efficacy signal, exVive3D provides the unique resolving power of a controlled human tissue microenvironment to investigate mechanism and develop solutions.

Click here to view the full press release.

The Conversation (0)
×